Asthma Drugs Market Size Worth $34.13Bn, Globally, by 2028 at 5% CAGR

The asthma drugs market size is projected to reach $34.13 billion in 2028 from $24.23 billion in 2021; it is estimated to grow at a CAGR of 5.0% during 2021–2028.

/EIN News/ — New York, May 04, 2022 (GLOBE NEWSWIRE) — The Insight Partners published latest research study on “Asthma Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Medications (Quick Relief Medications and Long-Term Control Medications), Route of Administration (Inhaled, Prefilled Syringes/Vials, and Others), and Distribution Channels (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies)”, the global asthma drugs market growth is driven by the growing environmental implications & genetic implications of air pollution, more vulnerability in specific ethnic groups, growing exposure to coarse particulate matters, and the growing prevalence of physiological disorders harboring asthma. The unmet medical needs and the lack of treatment adherence are the leading restraints that will hinder the market growth.

The Sample Pages Showcases Content Structure and Nature of Information Included in This Research Study Which Presents A Qualitative and Quantitative Analysis: https://www.theinsightpartners.com/sample/TIPRE00021879/

Asthma Drugs Market: Competitive Landscape and Key Developments
AstraZeneca, TEVA PHARMACEUTICAL INDUSTRIES LTD, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Koninklijke Philips N.V., Sanofi, Pfizer Inc. (Arena Pharmaceutical GmbH), Novartis AG, and Abbott, implemented various organic strategies, such as partnerships and collaborations, which bought dynamic improvements in the asthma drugs market share. Various companies are also adopting organic strategies, such as product launches and expansions, to expand their business and enhance their geographic presence. Additionally, product launch and expansion help market players strengthen their customer base and expand the product portfolio.

In February 2022, The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided a positive opinion recommending approval for Sanofi’s Dupixent (dupilumab) as an add-on maintenance therapy to treat children of the age of 6 to 11 years with severe asthma with type 2 inflammation.

Schedule A Pre-Sale Discussion with The Author Team in A Slot That You Prefer to Address Queries on Scope of The Study, Customization, Introduction to Research Methodology, Assistance on Technologies and Market Definitions: https://www.theinsightpartners.com/inquiry/TIPRE00021879/

In January 2022, GlaxoSmithKline plc got product approval from the U.S. Food and Drug Administration (FDA) for a 40 mg prefilled syringe of Nucala (mepolizumab) for children aged 6 to 11 years old having severe eosinophilic asthma (SEA). Nucala can now be given by a child’s health care provider or administered at home by a caregiver once trained by a health care professional. Nucala is an add-on, prescription maintenance treatment for patients six years and older with severe eosinophilic asthma.

In December 2021, AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) got approval in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine. It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase II and III clinical trials, which included a broad population of severe asthma patients irrespective of key biomarkers, including blood eosinophil counts and allergic status and fractional exhaled nitric oxide (FeNO).

In November 2021, AstraZeneca agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). The agreement ensured continued patient access to these established medicines. Covis Pharma previously acquired the rights to the respiratory medicines Alvesco, Omnaris, and Zetonna from AstraZeneca in 2018.

In July 2021, AstraZeneca’s Biologics License Application (BLA) for tezepelumab was accepted and granted Priority Review for the treatment of asthma by the U.S. Food and Drug Administration (FDA). AstraZeneca is developing Tezepelumab in collaboration with Amgen.

Click Here to Avail Lucrative DISCOUNTS on Our Latest Research Reports. We Offer Student, Enterprise, and Special Periodic Discounts to Our Clientele. Please Fill the Form to Know DISCOUNTED PRICE

In June 2021, Teva Pharmaceuticals, the US affiliate of Teva Pharmaceutical Industries Ltd., announced its US launch of the first generic version of twice daily PERFOROMIST, formoterol fumarate inhalation solution, 20 mcg/2 ML, indicated to treat bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

In March 2021, The US Food and Drug Administration approved three new ADCs to treat various cancers. The three ADCs approved included Genentech’s Polivy, Astellas Pharma, and Seattle Genetics’ Padcev, using the payload-linker combo from one of the early ADC successes. All three drugs featured a linker containing valine and citrulline’s amino acid combination.

Global Asthma Drugs Market: Key Insights – Future Trends
The treatment and management therapies for asthma continued to develop with various drugs in the pipeline. Tezepelumab is a recently FDA-approved injection as an add-on maintenance treatment to improve severe asthma symptoms and is also used in patients’ current asthma medicines. Tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine (cell-signaling proteins). Similarly, Masitinib, developed by AB Science, is an orally administered tyrosine kinase inhibitor that targets mast cells through inhibition of tyrosine kinases c-Kit, LYN, and FYN; it has recently been granted authorization by the French Medicine Agency to initiate a Phase III study to evaluate the drug in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS).

Have A 15-Minute-Long Discussion with The Lead Research Analyst and Author of The Report in A Time Slot Decided by You. You Will Be Briefed About the Contents of The Report and Queries Regarding the Scope of The Document Will Be Addressed as Well: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00021879

Astegolimab is another promising monoclonal antibody showing promising efficacy in reducing asthma exacerbation rates. The emphasis on precision medicine for asthma control through the development of new asthma guidelines is also expected to create a positive change toward asthma drugs and individualized care. Moreover, in 2020, the FDA approved the triple therapy of fluticasone furoate, umeclidinium, and vilanterol (Trelegy Ellipta, GSK) to treat asthma in patients aged 18 years and older. The approval was based on the clinical study of asthma patients receiving triple therapy through a single inhaler (CAPTAIN) study, which showed significant improvements in lung function after using the triple therapy compared to fluticasone furoate and vilanterol in a single daily dose and an easy-to-use inhaler. 

Asthma Drugs Market: Segmental Overview
Based on medications, the asthma drugs market is divided into quick relief medications and long-term control medications. The long-term control medications segment held a larger share in 2021. However, the quick relief medications segment is anticipated to register a higher CAGR over the forecast period. Quick-relief inhalers, also known as rescue inhalers, are short-term drugs used to treat acute asthma symptoms such as wheezing, chest tightness, shortness of breath, and coughing. A quick-relief inhaler can be carried by everyone who is suffering from asthma. It could be the only treatment for asthma attacks that are not severe. Moreover, intermittent asthma refers to asthma attacks that occur twice a week or fewer, with overnight symptoms occurring no more than twice a month.

Immediate Delivery of Our Off-The-Shelf Reports and Latest Research Studies, Through Flexible and Convenient Payment Methods: https://www.theinsightpartners.com/buy/TIPRE00021879/

Browse Adjoining Reports:
Anti Asthma Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type of Asthma (Allergic, Non- allergic); Asthma trigger type (Child-Onset Asthma, Adult-Onset Asthma, Exercise-Induced Asthma, Cough-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma); Drug Class (Bronchodilators, Leukotriene Antagonists, Mast Cell Stabilizers, Corticosteroids, Monoclonal Antibody); Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous) and Geography

Asthma Inhaler Device Market Forecast to 2028 – Covid-19 Impact and Global Analysis – by Type (Metered Dose inhaler, MDI with a spacer, Dry Powder inhaler, Others.); Technology (Manually operated inhaler, Digitally operated inhaler); End User (Hospitals, Clinics, Research Institutes, Others.)

Pediatric Asthma Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product type (Dry powder inhalers, Metered dose inhalers, Mist inhalers, Nebulizer); Drug class (Anti-inflammatory drugs, Bronchodilators, Combination therapy); Route of administration (Oral, Inhaled, Intravenous, Subcutaneous) and Geography

Asthma Therapeutics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type (Dry powder inhalers, Metered dose inhalers, Mist inhalers, Nebulizer); Drug Class (Anti-inflammatory drugs, Bronchodilators, Combination therapy); Route of administration (Oral, Inhaled, Intravenous, Subcutaneous) and Geography

Asthma Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Inhalers, Nebulizers, Dry Powder Inhalers, Metered-Dose Inhalers, Mesh Nebulizers); Technology (Manually Operated, Digitally Operated); End Users (Hospital, Retail Pharmacies) and Geography

Asthma And COPD Drugs Market Forecast to 2028 – Covid-19 Impact and Global Analysis – by Disease (COPD, Asthma); Medication Class (Combination Products, LTA, ICS, Anti cholinergic, SABA, LABA, Others.)

Nebulizers, Inhalers and Respirators for Asthma Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Nebulizers, Inhalers, Respirators); Application (Hospitals and Clinics, Home Care, Others), and geography

Adult Manual Resuscitator Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type ( Self inflating Resuscitator, Flow inflating Resuscitator, T piece ); Modality ( Disposable, Reusable ); Material ( Silicon, PVC, Rubber ); Technology ( Pop off valve, PEEP Valve, Others ); Patient Type ( Adult, Pediatric ); Applications ( Chronic obstructive pulmonary disease, Cardiopulmonary arrest, Anesthesia, Asthma ), Impact of covid-19 pandemic.

Pulmonary Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Others); Application (Asthma and COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Pediatric Healthcare Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Type Of Disease (Chronic Diseases, Acute Diseases) ; Indication (Asthma and allergies, Diabetes, Obesity, Cardiac Disorders, Genetic Disorders, Others) ; Treatment (Immunotherapy, Medications, Surgeries, Others) and Geography

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/asthma-drugs-market